Jay L. Patel,
MD, MBA
Languages Spoken: English
Dr. Patel is an associate professor of pathology at the University of Utah School of Medicine. In addition, Dr. Patel serves as Executive Director of Clinical Trials & PharmaDx at ARUP Laboratories. He received his MD from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. Dr. Patel then served as a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology. He is keen on application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.
Specialties
Board Certification and Academic Information
| Academic Departments | Pathology
-
Associate Professor (Clinical) |
| Academic Divisions | Clinical Pathology |
| Board Certification | American Board of Pathology (Anatomic & Clinical) American Board of Pathology (Sub: Hematology) |
Dr. Patel is an associate professor of pathology at the University of Utah School of Medicine. In addition, Dr. Patel serves as Executive Director of Clinical Trials & PharmaDx at ARUP Laboratories. He received his MD from the University of Arizona and completed a residency in anatomic and clinical pathology at the University of Utah. Dr. Patel then served as a hematopathology fellow at Stanford University. He is certified by the American Board of Pathology in anatomic and clinical pathology, with subspecialty boards in hematology. Dr. Patel’s clinical and research interests are broad and include all aspects of hematopathology. He is keen on application of next-generation sequencing technologies in the diagnosis and prognostication of hematolymphoid malignancies and benign hematologic disorders.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Pathology
-
Associate Professor (Clinical) |
| Academic Divisions | Clinical Pathology |
| Board Certification | American Board of Pathology (Anatomic & Clinical) American Board of Pathology (Sub: Hematology) |
Education History
| Graduate Training | University of Utah Business Management M.B.A., 2018 |
| Fellowship | Stanford University Hematopathology Fellow, 2011 |
| Residency | University of Utah Anatomic and Clinical Pathology Resident, 2010 |
| Professional Medical | University of Arizona Medicine M.D., 2006 |
| Undergraduate | University of Arizona Molecular & Cellular Biology B.S., 2002 |
Selected Publications - Journal Articles
Journal Article
- Li P, Brown S, Williams M, White TA, Xie W, Cui W, Peker D, Lei L, Kunder CA, Wang HY, Murray SS, Vagher J, Kovacsovics T, Patel JL (2022). The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood, 140, 716-755.
- Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal G (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. J Natl Compr Canc Netw, 1-4.
- Li P, White T, Xie W, Cui W, Peker D, Zeng G, Wang HY, Vagher J, Brown S, Williams M, Kovacsovics T, Patel JL (2021). AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia, 36, 664-674.
- Osman A, Patel JL (2021). Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clin Chem, 67, 1062-1070.
- Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI (2020). Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol, 43(3), 426-432.
- Sireci AN, Patel JL, Joseph L, Hiemenz MC, Rosca OC, Caughron SK, Thibault-Sennett SA, Burke TL, Aisner DL (2020). *Denotes equal contribution. Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement: A Report of the Association for Molecular Pathology. J Mol Diagn, 22(8), 975-993.
- Mansoor A, Mansoor MO, Patel JL, Zhao S, Natkunam Y, Bieker JJ (2020). KLF1/EKLF expression in acute leukemia is correlated with chromosomal abnormalities. Blood Cells Mol Dis, 83, 102434.
- Schumacher JA, Holgard VD, Sial F, Pearson LN, Patel JL, Karner KH (2019). Detection and Quantification of FLT3 Internal Tandem Duplication Mutations Do Not Vary Significantly Between Whole Blood and Blast-Enriched Samples. Am J Clin Pathol, 153(2), 251-257.
- Karner K, George TI, Patel JL (2019). Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. Ann Lab Med, 39(6), 509-514.
- Cessna MH, Paulraj P, Hilton B, Sadre-Bazzaz K, Szankasi P, Cluff A, Patel JL, Hoda D, Toydemir RM (2019). Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. Cancer Genet, 238, 31-36.
- Corean JLE, George TI, Patel JL, Li KD (2019). Bone marrow findings in metastatic melanoma, including role of BRAF immunohistochemistry. Int J Lab Hematol, 41(4), 550-560.
- Shen W, Paxton CN, Szankasi P, Longhurst M, Schumacher JA, Frizzell KA, Sorrells SM, Clayton AL, Jattani RP, Patel JL, Toydemir R, Kelley TW, Xu X (2017). Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing. J Clin Pathol, 71(4), 372-378.
- Sangle NA, Schmidt RL, Patel JL, Medeiros LJ, Agarwal AM, Perkins SL, Salama ME (2014). Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol, 27(8), 1137-43.